X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ J-Brain Cargo®, blood-brain barrier penetrating technology to develop highly innovative brain-penetrant biologic therapeutics in epilepsy.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: JCR Pharmaceuticals
Deal Size: $505.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 11, 2023
Details:
Cenobamate – under the brand name ONTOZRY® – has been commercialized in five major European countries such as Germany, the UK, Italy, Spain, and France, accounting for about 73 percent of the total value of the continent’s epilepsy market.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Ontozry
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: SK Biopharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
Ontozry (cenobamate) is a novel small molecule that provides a dual, complementary mechanism of action aimed at treatment of seizures also known as focal-onset seizures.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Ontozry
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Pivotal trial has demonstrated that Ontozry (cenobamate) at doses of 100 mg, 200 mg, and 400 mg/day significantly improved seizure control versus placebo for adult patients with focal-onset seizures taking 1-3 ASMs.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Ontozry
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
Following Angelini Pharma’s acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom).
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Xcopri
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Arvelle Therapeutics
Deal Size: $960.0 million Upfront Cash: $960.0 million
Deal Type: Acquisition January 04, 2021
Details:
Latuda becomes the first 2nd generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age. In addition to the new indication, Latuda was also granted an additional year of marketing protection.
Lead Product(s): Lurasidone
Therapeutic Area: Psychiatry/Psychology Product Name: Latuda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sunovion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 for the treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Kingdom and Russia.
Lead Product(s): Gaboxadol
Therapeutic Area: Genetic Disease Product Name: OV101
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Ovid Therapeutics
Deal Size: $232.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement July 13, 2020
Details:
The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its International presence.
Lead Product(s): Camphor,Capsicum oleoresin,Menthol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
